Nat Genet:“罕见突变”对银屑病影响或有限

2013-11-14 黄明明 中国科学报

近日,安徽医科大学、深圳华大基因研究院等单位的研究人员对21309名中国银屑病患者和对照的目标区域基因测序研究确认,“罕见突变”对银屑病的影响可能很有限。相关研究成果已在最新一期的《自然—遗传学》杂志上发表。【原文下载】 银屑病俗称“牛皮癣”,是一种常见的慢性炎症性皮肤病。此前,主流学说普遍认为,在人群中频率较低的罕见突变与复杂性遗传疾病的发生关系密切。 科研人员对781位银屑病患者以及676

近日,安徽医科大学、深圳华大基因研究院等单位的研究人员对21309名中国银屑病患者和对照的目标区域基因测序研究确认,“罕见突变”对银屑病的影响可能很有限。相关研究成果已在最新一期的《自然—遗传学》杂志上发表。【原文下载

银屑病俗称“牛皮癣”,是一种常见的慢性炎症性皮肤病。此前,主流学说普遍认为,在人群中频率较低的罕见突变与复杂性遗传疾病的发生关系密切。

科研人员对781位银屑病患者以及676位健康对照者的样本进行了外显子测序,希望发现更多遗传因素的证据。他们用数据分析的方法,检测到518308个单核苷酸变异(SNVs),其中,20.62%的SNVs是非同义突变,68.13%是罕见突变(<1%的等位基因频率)。考虑到外显子研究阶段样本量有限,研究者们在第二阶段又进一步对9946位银屑病患者和9906位健康对照者的样本进行了靶向测序研究。他们共分析了1326个靶向基因,包括622个与免疫调节相关的基因,发现了82387个非同义突变的SNVs,其中罕见突变所占比例高达97.07%。

经进一步分析,科研人员在IL23R和GJB2这两个基因上检测到与全基因组关联分析(GWAS)信号独立的低频(1%~5%的等位基因频率)错义突变关联信号;在LCE3D、ERAP1、CARD14 和ZNF816A这几个基因中,检测到5个可能是致病突变的常见错义突变与银屑病的发生显着关联。

此外,研究者们还认为,在FUT2 和TARBP1这两个基因上发现的罕见错义突变可能也与银屑病的发生有关,但其关联没有达到全基因组显着水平。在以基因为单位的检验中,也没有发现罕见突变在对照和患者中的分布有明显差异。此结果显示,目标区域编码区的低频和罕见非同义突变对银屑病的发生可能影响有限。

原文出处

Tang H, Jin X, Li Y, Jiang H, Tang X, Yang X, Cheng H, Qiu Y, Chen G, Mei J, Zhou F, Wu R, Zuo X, Zhang Y, Zheng X, Cai Q, Yin X, Quan C, Shao H, Cui Y, Tian F, Zhao X, Liu H, Xiao F, Xu F, Han J, Shi D, Zhang A, Zhou C, Li Q, Fan X, Lin L, Tian H, Wang Z, Fu H, Wang F, Yang B, Huang S, Liang B, Xie X, Ren Y, Gu Q, Wen G, Sun Y, Wu X, Dang L, Xia M, Shan J, Li T, Yang L, Zhang X, Li Y, He C, Xu A, Wei L, Zhao X, Gao X, Xu J, Zhang F, Zhang J, Li Y, Sun L, Liu J, Chen R, Yang S, Wang J, Zhang X.A large-scale screen for coding variants predisposing to psoriasis.Nat Genet. 2013 Nov 10.【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879752, encodeId=02f318e975280, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 25 08:19:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685917, encodeId=07ca168591e81, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 18:19:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048545, encodeId=d6142048545b0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu May 01 05:19:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733661, encodeId=92ed1e3366173, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 17 02:19:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467035, encodeId=8ab0146e03568, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 16 07:19:00 CST 2013, time=2013-11-16, status=1, ipAttribution=)]
    2014-04-25 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879752, encodeId=02f318e975280, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 25 08:19:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685917, encodeId=07ca168591e81, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 18:19:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048545, encodeId=d6142048545b0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu May 01 05:19:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733661, encodeId=92ed1e3366173, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 17 02:19:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467035, encodeId=8ab0146e03568, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 16 07:19:00 CST 2013, time=2013-11-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879752, encodeId=02f318e975280, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 25 08:19:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685917, encodeId=07ca168591e81, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 18:19:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048545, encodeId=d6142048545b0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu May 01 05:19:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733661, encodeId=92ed1e3366173, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 17 02:19:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467035, encodeId=8ab0146e03568, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 16 07:19:00 CST 2013, time=2013-11-16, status=1, ipAttribution=)]
    2014-05-01 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1879752, encodeId=02f318e975280, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 25 08:19:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685917, encodeId=07ca168591e81, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 18:19:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048545, encodeId=d6142048545b0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu May 01 05:19:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733661, encodeId=92ed1e3366173, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 17 02:19:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467035, encodeId=8ab0146e03568, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 16 07:19:00 CST 2013, time=2013-11-16, status=1, ipAttribution=)]
    2014-04-17 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=1879752, encodeId=02f318e975280, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 25 08:19:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685917, encodeId=07ca168591e81, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 18:19:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048545, encodeId=d6142048545b0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu May 01 05:19:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733661, encodeId=92ed1e3366173, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 17 02:19:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467035, encodeId=8ab0146e03568, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 16 07:19:00 CST 2013, time=2013-11-16, status=1, ipAttribution=)]
    2013-11-16 syscxl

相关资讯

诺华旗下Secukinumab在银屑病临床研究中胜过依那西普

诺华旗下Secukinumab的一项III期临床试验显示,这款抗体药物与安进/辉瑞的重磅炸弹级产品依那西普相比,在治疗斑块状银屑病方面更加有效。这项名为FIXTURE的临床试验由1300多名受试者参与,该试验将Secukinumab与依那西普进行了对比,结果显示经过12周的治疗之后,诺华这款药物的所有检测指标均达预期目标,并在两项关键疗效指标上超过其竞争对手依那西普,这两项指标为银屑病面积和严重程

ARD:合并银屑病的脊柱关节病患者疾病活动度更高

银屑病是脊柱关节病常见的临床表现。然而,银屑病对有炎性下腰背痛(IBP)患者的临床、功能和影像特征的影响与脊柱关节病的相关性尚不明确。为进一步确定脊柱关节病的患病率及其对近期发病的可能诊断为脊柱关节病的IBP患者的影响。 在DESIR队列的692例患者(平均年龄33.3±8.5岁,女性占53.8%,58.3%的患者人白细胞抗原B27阳性)中,确定银屑病的患病率。比较有无银屑病的患者的人口学资料、

Nat Genet:大量的罕见基因突变对银屑病影响或有限

 目前,主流假说普遍认为在人群中频率较低的罕见突变与复杂性遗传疾病的发生有着莫大关系,但是此假说却没能在来自安徽医科大学张学军教授、深圳华大基因研究院等单位的研究人员进行的21,309名中国银屑病患者和对照的目标区域基因测序研究中得到验证。这意味着罕见突变对银屑病的影响可能很有限。最新研究成果已发表于最新一期的《自然•遗传学》杂志上。   银屑病是一种常见的慢性炎症性皮肤病,累及人群较广

AR:甲氨蝶呤或其他抗银屑病药物治疗对银屑病并发缺血性心脏病影响无差异

银屑病和缺血性心脏病(IHD)有相关性。之前的研究证实,甲氨蝶呤(MTX)可能能改善银屑病和类风湿关节炎患者的心血管疾病病情。针对这一情况,来自台湾台北市国立明阳大学的Yi-Ju Chen等人进行了一项研究,该研究的目的是比较甲氨蝶呤和其他非生物制剂抗银屑病药物治疗银屑病时,患者新发IHDs的风险差异。研究结果在线发布在2012年6月的《关节炎与风湿病》(ARTHRITIS & RHEUM

Nat Genet:张学军团队发现六个新银屑病易感基因

10月18日,国际著名学术期刊《自然—遗传学》(Nature Genetics)在线发表中外科学家合作研究发现6个新的银屑病易感基因的研究成果。这项研究由安徽医科大学第一附属医院张学军教授领衔,联合美国密歇根大学、华盛顿大学,德国吉尔大学和复旦大学华山医院等国内外30多家单位共同参与完成。这项研究分别得到国家自然科学基金重点项目、国家“973”计划项目、“863”计划项目和美国NIH项目支持。&n

银屑病与慢性肾病有关

研究人员首次声明称他们发现了中重度银屑病与慢性肾病(CKD)之间的一个联系。据费城宾夕法尼亚大学Perelman医学院皮肤病及流行病学助理教授Joel M. Gelfand和他的同事称,在一项匹配队列研究中,治疗记录取代了疾病的严重程度,重度银屑病病人CKD的发病率要比那些中等程度银屑病病人高将近两倍(校正后OR1.93 VS 0.99)。 在他们在线发表于BMJ杂志的研究中,他们称,CKD的风